CEL-SCI Corporation (CVM)

NYSEAMERICAN: CVM · Real-Time Price · USD
0.828
-0.046 (-5.21%)
Nov 4, 2024, 4:00 PM EST - Market closed
-5.21%
Market Cap 50.89M
Revenue (ttm) n/a
Net Income (ttm) -29.10M
Shares Out 61.49M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 471,447
Open 0.880
Previous Close 0.873
Day's Range 0.800 - 0.886
52-Week Range 0.800 - 3.230
Beta 0.69
Analysts n/a
Price Target n/a
Earnings Date Dec 19, 2024

About CVM

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company’s lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune sy... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 1, 1987
Employees 43
Stock Exchange NYSEAMERICAN
Ticker Symbol CVM
Full Company Profile

Financial Performance

Financial Statements

News

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--FDA's ODAC decision on checkpoint inhibitors substantiates potential of Multikine to address major treatment gap for PD-L1 negative cancer patients.

13 days ago - Business Wire

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI selects Ergomed as CRO as it gears up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer.

4 weeks ago - Business Wire

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO2024--CEL-SCI's Multikine Increased 5-Year Survival Rate in Locally Advanced Resectable Head & Neck Cancer Patients Deemed to be in the Treatment Group.

7 weeks ago - Business Wire

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #ESMO24--CEL-SCI to present new data for Multikine head & neck cancer immunotherapy at the European Society for Medical Oncology 2024 Congress.

7 weeks ago - Business Wire

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--The UK's Medicines & Healthcare Products Regulatory Agency grants CEL-SCI a pediatric waiver for Multikine.

2 months ago - Business Wire

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports third quarter fiscal 2024 financial results, as well as key recent clinical and corporate developments.

2 months ago - Business Wire

CEL-SCI Announces Closing of $10.8 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $10.8 million offering.

3 months ago - Business Wire

CEL-SCI Announces Pricing of $10.8 Million Offering

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces pricing of $10.8 million offering .

3 months ago - Business Wire

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI's phase 3 population analysis for upcoming confirmatory registration study in head & neck cancer demonstrates well balanced patient population...

3 months ago - Business Wire

CEL-SCI Appoints Robert Watson as Chairperson of the Board

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI appoints Robert Watson as Chairperson of the Board.

4 months ago - Business Wire

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation (NYSE American: CVM) today announced the Company's Chief Scientific Officer, Dr. Eyal Talor, delivered a presentation titled “Neoa...

4 months ago - Business Wire

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Dr. Giovanni Selvaggi, who has brought several oncology drugs to market, joins CEL-SCI as Clinical Advisor.

5 months ago - Business Wire

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation reports second quarter fiscal 2024 financial results.

6 months ago - Business Wire

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI receives FDA go-ahead for its confirmatory study of Multikine in the treatment of head & neck cancer.

6 months ago - Business Wire

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI appoints Mario Gobbo to its Board of Directors.

6 months ago - Business Wire

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

NEW YORK--(BUSINESS WIRE)--Channel V Media (CVM), a communications strategy and PR firm that builds market momentum for both established enterprises and emerging venture‑backed innovators, today annou...

7 months ago - Business Wire

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI's LEAPS vaccine offers promising new paradigm to treat rheumatoid arthritis: published in Frontiers in Immunology.

8 months ago - Business Wire

CEL-SCI Corporation Issues Letter to Shareholders

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation issues letter to shareholders.

8 months ago - Business Wire

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results.

9 months ago - Business Wire

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI announces closing of $7.75 million public offering of common stock.

9 months ago - Business Wire

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI announces pricing of $7.75 million public offering of common stock.

9 months ago - Business Wire

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI completes commissioning of its Multikine manufacturing facility for commercial scale production of head & neck cancer drug.

9 months ago - Business Wire

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--European Medicines Agency grants CEL-SCI a waiver of strict pediatric requirements, clearing the path towards marketing authorization for Multikine.

9 months ago - Business Wire

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--CEL-SCI reports fiscal 2023 financial results and clinical & corporate developments.

11 months ago - Business Wire

UK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck Cancer

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--UK'S National Institute for Health and Care Excellence (NICE) selects Multikine as potential new standard of care for head & neck cancer.

1 year ago - Business Wire